- The “neoepitope” identification pipeline facilitates discovery of immunotherapy targets unique to individual cancer patients as a personalized and precision medicine approach to treatment
- The neoepitopes identified can be leveraged to improve outcomes with adoptive cell transfer therapy and personalized vaccines
- Adenovirus and Yeast vaccine platforms in Phase1/2 clinical trials to drive immunity to tumor-associated antigens and neoantigens across multiple solid tumor types
ImmunityBio, Inc. (NASDAQ:IBRX), a publicly traded immunotherapy company , and privately-held NantOmics today announced publication of a stepwise approach or “pipeline” for identification and validation of neoepitope and neoepitope-reactive T cells from individual patients. The identification of neoepitopes—short peptide sequences that are mutated in tumors and are capable of generating an immune response—provides critical support in the successful development of next-generation immunotherapies delivered by ImmunityBio’s Adeno- and yeast-based platforms. The pipeline is described in “Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy,” which recently published in the Journal for Immunotherapy of Cancer.
